157 related articles for article (PubMed ID: 12924538)
1. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
[TBL] [Abstract][Full Text] [Related]
4. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
Grub S; Delora P; Lüdin E; Duff F; Fletcher CV; Brundage RC; Kline MW; Calles NR; Schwarzwald H; Jorga K
Clin Pharmacol Ther; 2002 Mar; 71(3):122-30. PubMed ID: 11907486
[TBL] [Abstract][Full Text] [Related]
7. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
9. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
[TBL] [Abstract][Full Text] [Related]
11. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
Burger DM; Bergshoeff AS; De Groot R; Gibb D; Walker S; Tréluyer JM; Hoetelmans RM;
J Pediatr; 2004 Sep; 145(3):403-5. PubMed ID: 15343199
[TBL] [Abstract][Full Text] [Related]
12. Changes in indinavir exposure over time: a case study in six HIV-1-infected children.
Fraaij PL; Bergshoeff AS; van Rossum AM; Hartwig NG; Burger DM; de Groot R
J Antimicrob Chemother; 2003 Oct; 52(4):727-30. PubMed ID: 12917234
[TBL] [Abstract][Full Text] [Related]
13. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
14. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
15. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
[TBL] [Abstract][Full Text] [Related]
16. [Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].
de Alarcón A; Viciana P; Lozano F; Vergara A; Pujol E; Barrera A; Pérez-Guzmán E; Colmenero MA; Hernández-Quero J; Márquez M; de la Torre J; Aliaga L; Suárez I; Gutiérrez-Ravé V; Torres-Tortosa M; Marín J; Valdayo MJ; Milla M;
Enferm Infecc Microbiol Clin; 2003 Dec; 21(10):543-51. PubMed ID: 14642252
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
Villani P; Floridia M; Pirillo MF; Cusato M; Tamburrini E; Cavaliere AF; Guaraldi G; Vanzini C; Molinari A; degli Antoni A; Regazzi M
Br J Clin Pharmacol; 2006 Sep; 62(3):309-15. PubMed ID: 16934047
[TBL] [Abstract][Full Text] [Related]
18. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
[TBL] [Abstract][Full Text] [Related]
20. Low-dose ritonavir moderately enhances nelfinavir exposure.
Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
